Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.0035 USD
Change Today 0.00 / 0.00%
Volume 20.0K
VIRA On Other Exchanges
As of 8:10 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

viratech corp (VIRA) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/15/14 - $0.01
52 Week Low
12/5/14 - $0.0008
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for VIRATECH CORP (VIRA)

Related News

No related news articles were found.

viratech corp (VIRA) Related Businessweek News

No Related Businessweek News Found

viratech corp (VIRA) Details

Viratech Corp., an open source biotech research and development network, engages in developing cancer detection and treatment protocols in the United States. The company holds licenses to market cancer diagnostic and treatment protocols, including the unified cancer theory, the stage zero cancer protocol, and an early detection diagnostic system. It also operates a social networking Website focused on cancer research. The company was formerly known as Imperia Entertainment, Inc. and changed its name to Viratech Corp. in October 2011. Viratech Corp. was founded in 2000 and is based in Reno, Nevada.

3 Employees
Last Reported Date: 07/31/07
Founded in 2000

viratech corp (VIRA) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

viratech corp (VIRA) Key Developments

Viratech Corp. Announces Agreement for License of Technology Platform for Cancer Patients

Viratech Corp. announced the signing of an agreement for a license issued from Chris Ryan and Kevin Buckman for a patent-pending, provisional application titled ‘method of lowering a cancer patient's morbidity rate by increasing quality of life of patient by leveraging cause-based electronic social support networks’. This invention was created to lower morbidity in cancer patients by creating an online, cause-based Social Support Network (SSN) for the benefit of cancer patients based on the modular adaption, construction and best practices implementation of the European Organization for Research and Treatment of Cancer (EORTC), and Quality of Life Questionnaire-C30 (QLQ-C30). There are other benefits to cancer patients and this platform can be used for other medical disorders, like diabetes, heart diseases, or even as a business development platform. The social support network is made up of miniature social networks, called Micro Support Networks (MSN), which revolve around a single user, or Beneficiary, who is facing a particular challenge or obstacle related to cancer.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VIRA:US $0.00 USD 0.00

VIRA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VIRA.
View Industry Companies

Industry Analysis


Industry Average

Valuation VIRA Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 70.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VIRATECH CORP, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at